Latest On Innoviva, Inc (INVA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 18:17 EST | News | Innoviva, Entasis' bacterial pneumonia drug Xacduro wins FDA approval | N/A |  |
| 2023-05-10 04:00 EST | News | Innoviva GAAP EPS of $0.51, revenue of $76.37M | N/A | |
| 2023-04-28 20:42 EST | News | Innoviva chairman Bickerstaff to step down after annual meeting | N/A | |
| 2023-04-17 22:45 EST | News | Innoviva rises 6% on FDA panel backing for bacterial pneumonia drug | N/A | |
| 2023-03-17 10:16 EST | News | Still Avoiding Innoviva | N/A | |
About Innoviva, Inc (INVA):
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company read more...was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
General
- Name Innoviva, Inc
- Symbol INVA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 5
- Last Split Factor1241:1000
- Last Split Date2014-06-03
- Fiscal Year EndDecember
- IPO Date2004-10-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.inva.com
Valuation
- Trailing PE 5.87
- Price/Sales (Trailing 12 Mt.) 4
- Price/Book (Most Recent Quarter) 2.23
- Enterprise Value Revenue 3.98
- Enterprise Value EBITDA 3.47
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $1.69
- Next Year EPS Estimate $1.49
- Profit Margin 67%
- Operating Margin 96%
- Return on Assets 23%
- Return on Equity 62%
- Revenue 336.79 million
- Earnings Per Share $2.02
- Revenue Per Share $3.32
- Gross Profit 335.01 million
- Quarterly Earnings Growth 19.1%
Highlights
- Market Capitalization 1.2 billion
- EBITDA 322.84 million
- PE Ratio 8.34
- PEG Ratio 0.24
- Analyst Target Price $10
- Book Value Per Share $5.33
Share Statistics
- Shares Outstanding 101.39 million
- Shares Float 54.79 million
- % Held by Insiders 3197%
- % Held by Institutions 75.88%
- Shares Short 9.96 million
- Shares Short Prior Month 9.42 million
- Short Ratio 16.86
- Short % of Float 17%
- Short % of Shares Outstanding 10%
Technicals
- Beta 0.65
- 52 Week High $15.62
- 52 Week Low $8.13
- 50 Day Moving Average 11.92
- 200 Day Moving Average 11.36
Dividends
- Dividend Date 2015-09-30
- ExDividend Date 2015-09-08
- Dividend Per Share $N/A
- Dividend Yield 0%
Innoviva, Inc (INVA) Dividend Calendar:
INVA's last dividend payment was made to shareholders on September 30, 2015.
Innoviva, Inc (INVA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Innoviva, Inc (INVA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Innoviva, Inc (INVA) Chart:
Innoviva, Inc (INVA) News:
Below you will find a list of latest news for Innoviva, Inc (INVA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Innoviva, Inc (INVA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest INVA Trades:
Innoviva, Inc (INVA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-28 | 8-K (Current report) | |
| 2020-10-28 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-09-01 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-09-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-31 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-08-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-29 | 8-K (Current report) | |
| 2020-07-29 | 8-K (Current report) | |
| 2020-07-29 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-12 | 8-K (Current report) | |
| 2020-06-12 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-05-26 | 8-K (Current report) | |
| 2020-05-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-29 | 8-K (Current report) | |
| 2020-04-29 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-04-28 | 8-K (Current report) | |
Innoviva, Inc (INVA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Innoviva, Inc (INVA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3197%
Institutional Ownership: 7588%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-01 | Innoviva, Inc. | 10% Share Holder | Buy | 4,672,897.00 | 2.68 | 12,499,999.48 | 18,672,897.00 | |
| 2020-06-11 | Innoviva, Inc. | 10% Share Holder | Buy | 12,677,490.00 | 2.50 | 31,693,725.00 | 14,000,000.00 | |
| 2020-04-24 | Mark DiPaolo | Director | Buy | 16,917.00 | 58,082.00 | | ||
| 2020-04-24 | Sarah J. Schlesinger | Director | Buy | 16,917.00 | 58,082.00 | | ||
| 2020-04-24 | Kostas D Odysseas | Director | Buy | 16,917.00 | 62,078.00 | | ||
| 2020-04-24 | Jules Haimovitz | Director | Buy | 16,917.00 | 70,282.00 | | ||
| 2020-04-24 | George Bickerstaff | Director | Buy | 16,917.00 | 87,078.00 | | ||
| 2020-03-27 | Innoviva, Inc. | 10% Share Holder | Buy | 7,717,661.00 | 2.87 | 22,149,687.07 | 8,710,800.00 | |
| 2020-02-24 | Marianne Zhen | Chief Accounting Officer | Sell | 2,954.00 | 14.78 | 43,660.12 | 21,913.00 | |
| 2019-09-04 | GEOFFREY HULME | Interim PEO | Buy | 3,000.00 | 10.89 | 32,684.40 | 31,000.00 | |
| 2019-04-24 | Mark DiPaolo | Director | Buy | 16,399.00 | 41,165.00 | | ||
| 2019-04-24 | Sarah J. Schlesinger | Director | Buy | 16,399.00 | 41,165.00 | | ||
| 2019-04-24 | Kostas D Odysseas | Director | Buy | 16,399.00 | 45,161.00 | | ||
| 2019-04-24 | Jules Haimovitz | Director | Buy | 16,399.00 | 53,365.00 | | ||
| 2019-04-24 | George Bickerstaff | Director | Buy | 16,399.00 | 70,161.00 | | ||
| 2019-03-01 | Marianne Zhen | Chief Accounting Officer | Buy | 8,154.00 | 26,818.00 | | ||
| 2019-03-01 | GEOFFREY HULME | Interim PEO | Buy | 14,677.00 | 27,584.00 | | ||
| 2019-02-27 | George Bickerstaff | Director | Buy | 15,000.00 | 15.90 | 238,500.00 | 53,762.00 | |
| 2019-02-26 | Marianne Zhen | Chief Accounting Officer | Sell | 5,617.00 | 16.00 | 89,872.00 | 18,664.00 | |
| 2019-02-21 | George Bickerstaff | Director | Buy | 10,000.00 | 14.90 | 148,958.00 | 38,762.00 | |